Lilly Antibody Treatment Lands FDA Emergency Use Authorization

Indianapolis-based Eli Lilly and Co. has made a breakthrough in treating the coronavirus, one that will have huge global implications. The U.S. Food and Drug Administration has granted Emergency Use Authorization for a COVID-19 antibody therapy developed by Lilly scientists and researchers. The treatment, known as bamlanivimab will soon be available to treat recently diagnosed, high-risk patients. For more on the treatment, the timeline for when it will be administered and its significance for the pharmaceutical giant, we turn to Eli Lilly Chief Financial Officer Josh Smiley.

**FOLLOW US ON SOCIAL MEDIA**